Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.99B | 2.88B | 2.33B | 1.94B | 1.69B | 1.48B |
Gross Profit | 2.66B | 2.57B | 2.07B | 1.79B | 1.56B | 1.38B |
EBITDA | 1.56B | 1.65B | 1.39B | 1.04B | 736.80M | 646.30M |
Net Income | 1.21B | 1.20B | 984.80M | 727.30M | 475.80M | 514.80M |
Balance Sheet | ||||||
Total Assets | 4.64B | 7.36B | 7.17B | 6.04B | 5.17B | 4.62B |
Cash, Cash Equivalents and Short-Term Investments | 1.73B | 3.27B | 2.99B | 4.15B | 3.58B | 2.98B |
Total Debt | 800.00M | 300.00M | 700.00M | 800.00M | 800.00M | 800.00M |
Total Liabilities | 1.20B | 920.00M | 1.18B | 1.25B | 1.21B | 1.22B |
Stockholders Equity | 3.45B | 6.44B | 5.98B | 4.80B | 3.96B | 3.40B |
Cash Flow | ||||||
Free Cash Flow | 1.13B | 1.08B | 747.60M | 663.70M | 477.40M | 696.40M |
Operating Cash Flow | 1.41B | 1.33B | 978.00M | 802.50M | 598.20M | 755.70M |
Investing Cash Flow | -482.80M | 417.20M | -719.60M | -811.50M | -486.90M | -738.50M |
Financing Cash Flow | -280.60M | -1.25B | -11.90M | 75.40M | 44.80M | -16.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
84 Outperform | $11.91B | 20.00 | 30.22% | ― | 24.49% | 244.87% | |
78 Outperform | $12.72B | 11.60 | 22.69% | ― | 25.11% | 46.46% | |
76 Outperform | $12.82B | 11.47 | 19.94% | ― | 19.85% | 21.16% | |
74 Outperform | $13.30B | 212.65 | 0.47% | ― | 17.13% | -88.78% | |
71 Outperform | $10.58B | 20.40 | 9.64% | ― | 17.99% | 152.10% | |
53 Neutral | $15.30B | ― | -123.93% | ― | ― | -99.70% | |
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% |
On June 26, 2025, United Therapeutics held its Annual Meeting of Shareholders where four key matters were voted on. The shareholders elected directors for a one-year term, approved an advisory resolution on executive compensation, amended the 2015 Stock Incentive Plan, and ratified Ernst & Young LLP as the independent public accounting firm for 2025.
The most recent analyst rating on (UTHR) stock is a Hold with a $319.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
On April 25, 2025, United Therapeutics Corporation entered into a Credit Agreement with Wells Fargo and other lenders, establishing an unsecured revolving credit facility of up to $2.5 billion, with the possibility of increasing by an additional $750 million. The agreement allows for refinancing existing debt and supporting general corporate purposes. Concurrently, the company borrowed $200 million to repay its previous 2022 Credit Agreement, which was terminated without penalties.